A cellular and molecular biology-based update for ivermectin against COVID-19: is it effective or non-effective?
Mohsen Nabi-AfjadiFatemeh MohebiHamidreza ZalpoorFatemeh AziziyanAbdullatif AkbariHemen Moradi-SardarehElham BahreiniAmir Mansour MoeiniHossein EffatpanahPublished in: Inflammopharmacology (2023)
Despite community vaccination against coronavirus disease 2019 (COVID-19) and reduced mortality, there are still challenges in treatment options for the disease. Due to the continuous mutation of SARS-CoV-2 virus and the emergence of new strains, diversity in the use of existing antiviral drugs to combat the epidemic has become a crucial therapeutic chance. As a broad-spectrum antiparasitic and antiviral drug, ivermectin has traditionally been used to treat many types of disease, including DNA and RNA viral infections. Even so, based on currently available data, it is still controversial that ivermectin can be used as one of the effective antiviral agents to treat severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or not. The aim of this study was to provide comprehensive information on ivermectin, including its safety and efficacy, as well as its adverse effects in the treatment of COVID-19.
Keyphrases
- sars cov
- respiratory syndrome coronavirus
- coronavirus disease
- drug administration
- healthcare
- mental health
- single molecule
- escherichia coli
- emergency department
- type diabetes
- cardiovascular events
- circulating tumor
- electronic health record
- cell free
- cardiovascular disease
- drug induced
- big data
- risk factors
- deep learning